Prolonged disease‐free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma
Weiyun Z. Ai(City College of San Francisco), Ronald Levy(Hôpital Necker-Enfants Malades), Frank J. Hsu(Sanofi (France)), John M. Timmerman(Sheba Medical Center), Jimmy J. Hwang(University of California, San Francisco), Debra D. Czerwinski(Stanford University), Holbrook E. Kohrt(Stanford University), Behnaz Taidi
Cited by 1
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k